Clinical Trial Detail

NCT ID NCT03157128
Title Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Loxo Oncology, Inc.
Indications

thyroid medullary carcinoma

non-small cell lung carcinoma

Advanced Solid Tumor

Therapies

LOXO-292

Age Groups: adult senior

Additional content available in CKB BOOST